Back to Search Start Over

Efficacy and Safety Results of a Phase 1 Study of 177lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
126
Issue :
23
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs56868977
Full Text :
https://doi.org/10.1182/blood.V126.23.5118.5118